Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Metastatic Breast Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,113 result(s) found for: Metastatic Breast Cancer. Displaying page 8 of 56.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2010-020101-32 Sponsor Protocol Number: OAM4861g Start Date*: 2010-10-21
    Sponsor Name:GENENTECH, Inc.
    Full Title: A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF METMAB IN COMBINATION WITH PACLITAXEL AND BEVACIZUMAB IN PATIENTS WITH METASTATIC, ...
    Medical condition: Metastatic, triple-negative breast cancer Cáncer de mama metastásico triple negativo
    Disease: Version SOC Term Classification Code Term Level
    12.1 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) FR (Completed) BE (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005161-12 Sponsor Protocol Number: OAS-12DOC-BIO Start Date*: 2015-10-22
    Sponsor Name:Oasmia Pharmaceutical AB
    Full Title: A multi-country, multicenter, randomized, open-label, parallel group study to assess the efficacy and safety of Docecal compared with Taxotere®
    Medical condition: adenocarcinoma of the breast
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005238-40 Sponsor Protocol Number: EQ132-201 Start Date*: 2022-05-11
    Sponsor Name:EQRx, Inc.
    Full Title: A Phase 2 Study to Evaluate the Safety and Efficacy of Lerociclib in Participants with Advanced Breast Cancer
    Medical condition: Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    20.0 100000004872 10006289 Benign and malignant breast neoplasms HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006290 Breast and nipple neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003036-31 Sponsor Protocol Number: 01B Start Date*: 2012-03-20
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI
    Full Title: Ministry of health integrated oncological program n°5/2006: 18F-Fluorometilcholine (18FFCH) PET/CT sensibility in diagnosis of breast cancer metastasis
    Medical condition: de novo breast cancer metastasis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-006060-29 Sponsor Protocol Number: FARM6N78KN Start Date*: 2008-11-21
    Sponsor Name:IST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO
    Full Title: Efficacy and toxicity of Trastuzumab at the maintaining dose of 1 mg/kg/week versus the standard dose of 2 mg/kg/week in combination with chemotherapy in metastatic breast cancer patients. A phase ...
    Medical condition: HER-2 positive metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001246-36 Sponsor Protocol Number: ACE-Breast-03 Start Date*: 2022-02-22
    Sponsor Name:Ambrx, Inc.
    Full Title: A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Whose Disease is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinib-containing Regimens
    Medical condition: Metastatic Breast Cancer Resistant or Refractory
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) ES (Prematurely Ended) IT (Prematurely Ended) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001916-18 Sponsor Protocol Number: 20080331 Start Date*: 2008-11-05
    Sponsor Name:AZIENDA OSPEDALIERA ORDINE MAURIZIANO
    Full Title: A phase II, randomized trial with single agent trastuzumab or lapatinib in women with metastatic breast cancer iperexpressing HER2
    Medical condition: women with metastatic breast cancer iperexpressing HER2
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065430 LLT
    9.1 10055113 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002707-18 Sponsor Protocol Number: EFFECT Start Date*: 2012-11-14
    Sponsor Name:FONDAZIONE SANDRO PITIGLIANI PER LA LOTTA CONTRO I TUMORI-ONLUS
    Full Title: EFFECT: A randomized phase II study to evaluate the EFficacy and impact on Function of two different doses of nab-paclitaxEl in elderly patients with advanCed breasT cancer
    Medical condition: Patients aged 65 years or older with histologically or cytologically confirmed breast cancer, locally recurrent and/or metastatic; any estrogen/progesterone receptor status; HER2 receptor negative ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005335-97 Sponsor Protocol Number: GO25632 Start Date*: 2012-10-11
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of bevacizumab, and associated biomarkers, in combination with paclitaxel compared w...
    Medical condition: HER2-negative metastatic breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002669-38 Sponsor Protocol Number: 0822-016 Start Date*: 2006-12-07
    Sponsor Name:Merck & Co Inc.
    Full Title: A Phase II Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Women with Breast Cancer and Established Bone Metastases (MBD)
    Medical condition: Metastatic Bone Disease (MBD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027452 Metastases to bone LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) NO (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000572-14 Sponsor Protocol Number: EFC6088 (XRP9881B/2001) Start Date*: 2004-10-08
    Sponsor Name:Aventis Pharmaceuticals, Inc. (a subsidiary of sanofi-aventis group)
    Full Title: Phase II multicenter, open label, non-randomized study of intravenous RPR109881 q 3 weeks in patients with metastatic breast cancer progressing after therapy with anthracyclines, taxanes, and capec...
    Medical condition: Metastatic breast cancer patients after failure to anthracyclines, taxanes and capecitabine.
    Disease: Version SOC Term Classification Code Term Level
    10055113
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) IT (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003283-20 Sponsor Protocol Number: MO21926 Start Date*: 2009-02-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Estudio de fase II abierto, con un solo grupo de tratamiento, de bevacizumab en combinación con trastuzumab y capecitabina como tratamiento en primera línea de pacientes con cáncer de mama localmen...
    Medical condition: Tratamiento de pacientes con cáncer de mama localmente recurrente o metastásico HER2- positivo que no han recibido previamente quimioterapia para enfermedad localmente recurrente o metastásica. H...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    9.1 10065430 HER-2 positive breast cancer LLT
    9.1 10006198 Breast cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Ongoing) SE (Completed) SK (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-001765-41 Sponsor Protocol Number: 1200.137 Start Date*: 2012-02-13
    Sponsor Name:Medizinische Fakultät der Otto-von-Guericke Universität Magdeburg Universitätsklinikum Magdeburg A.ö.R.
    Full Title: Single-arm, open-label, multicentre phase II study evaluating the efficacy and safety of BIBW 2992 (Afatinib) in combination with vinorelbine for the treatment of patients with metastatic breast ca...
    Medical condition: Metastatic breast cancer patients with intermediate HER2 expression (IHC 2+, HER2 FISH-negative)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003435-13 Sponsor Protocol Number: MARLENE Start Date*: 2021-05-27
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Metronomic vinorelbin, cyclophosphamide and capecitabine after progression to cyclin-dependent kinase 4/6 inhibitors for hormone receptors positive HER2 negative metastatic breast cancer
    Medical condition: HER2 negative hormone receptors positive metastatic breast cancer progressed after CDK 4/6 inhibitors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10007310 Carcinoma breast stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000245-13 Sponsor Protocol Number: SOLTI-1907 Start Date*: 2021-03-04
    Sponsor Name:SOLTI
    Full Title: A Phase II with 2 parallel cohorts clinical trial targeting estrogen receptor negative or PAM50 non-luminal disease with Atezolizumab in combination with Trastuzumab and Vinorelbine in HER2-positiv...
    Medical condition: Pre- and post-menopausal women with locally advanced or metastatic HER2-positive breast cancer who have progressed to trastuzumab/pertuzumab and T-DM1.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005021-30 Sponsor Protocol Number: FARM5P8YFC Start Date*: 2007-10-31
    Sponsor Name:REGIONE LOMBARDIA - DIREZIONE GENERALE SANITA'
    Full Title: TOP TRIAL. A RANDOMISED PHASE III CLINICAL TRIAL OF TRASTUZUMAB (HERCEPTIN) OPTIMIZATION IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC BREAST CANCER OVEREXPRESSING HER2 AFTER A FIRST LINE CHE...
    Medical condition: Women with locally advanced or metastatic breast cancer over expressing HER2 who have been previously treated with a first line chemotherapy plus trastuzumab.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006279 Breast neoplasm LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001938-35 Sponsor Protocol Number: IFG-06-2019 Start Date*: 2020-10-02
    Sponsor Name:Institut für Frauengesundheit GmbH
    Full Title: AIRE: – ASSESSING IMMUNORESPONSE POST ERIBULIN: ERIBULIN AND IMMUNOGENICITY IN ADVANCED BREAST CANCER – A PROSPECTIVELY RANDOMIZED PHASE IV STUDY
    Medical condition: Female patients diagnosed with HER2 negative advanced breast cancer, which had received at least one previous chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-006109-19 Sponsor Protocol Number: STM01-102 Start Date*: 2006-09-08
    Sponsor Name:Sopherion Therapeutics, Inc.
    Full Title: A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel versus Trastuzumab and Paclitaxel for First line Therapy of Metastatic Breast Cancer
    Medical condition: HER2+ Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027475 llt
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PT (Completed) DE (Completed) ES (Prematurely Ended) GB (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003994-28 Sponsor Protocol Number: VinCaT Start Date*: 2006-11-10
    Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE "G. PASCALE"
    Full Title: VINORELBINE, CARBOPLATIN AND TRASTUZUMAB IN ADVANCED HER-2 POSITIVE BREAST CANCER. A PHASE 2 STUDY
    Medical condition: BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055113 Breast cancer metastatic LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004848-23 Sponsor Protocol Number: 89/2006/O/Sper Start Date*: 2006-09-12
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Sequential Oral Therapy (SOT trial) in elderly patients with metastatic breast cancer: a phase IV randomized trial
    Medical condition: breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006279 Breast neoplasm LLT
    Population Age: Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 22 19:05:51 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA